- Sustainability Strategy and Goals
- Technology and Innovation
- Global Partnerships and Advocacy
- Progress vs. Target Tracker
- Key Sustainability Innovations and Technologies
- Measurable Impacts
- Challenges and Areas for Improvement
- Future Plans and Long-Term Goals
- Comparisons to Industry Competitors
- Climate and Circularity Metrics
- What to Watch: 12 to 18 Month Indicators
Johnson & Johnson (J&J) anchors sustainability in its Health for Humanity strategy, which connects ESG to its core purpose of improving health while managing environmental and social risks across a two‑segment business in Innovative Medicine and MedTech. The 2024 ESG Summary shows rapid progress in renewable electricity and waste diversion, strong global health contributions, and areas where climate and packaging ambitions still require deeper execution.
- In 2024 J&J reduced absolute Scope 1 and 2 greenhouse gas emissions to 430,926 tCO₂e, down from 514,693 tCO₂e in 2022, and reports a 26% cut since 2021.
- 88% of global electricity came from renewable sources in 2024, up from 75% in 2022, as the company moves toward 100% renewable electricity by 2025.
- J&J diverted 125,070 metric tonnes of waste from disposal in 2024 versus 100,510 tonnes in 2023, while waste sent to disposal fell from 28,915 tonnes in 2022 to 17,446 tonnes in 2024.
- Total water withdrawn dropped from 11.11 million m³ in 2022 to 7.43 million m³ in 2024, a reduction of about one‑third in two years.
- J&J has ranked in the top five of the Access to Medicine Index for more than a decade, including a top‑five position again in the latest 2024 index.
Source
https://healthforhumanityreport.jnj.com/2024/
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
https://accesstomedicinefoundation.org/company/johnson-johnson
Sustainability Strategy and Goals
J&J’s ESG strategy is built around four pillars, innovation and advancing health for all, empowering employees, advancing environmental health, and accountability and governance, overseen by the Board and an Enterprise Compliance & Risk Committee. Climate goals are validated by external initiatives such as the Science Based Targets initiative and Net Zero Tracker, with a net zero 2045 target that covers Scope 1, 2, and 3 emissions.
- J&J aims to reach net‑zero emissions across its full value chain by 2045, with carbon neutrality in global operations (Scopes 1 and 2) by 2030.
- Operational goals include sourcing 100% of electricity from renewable sources by 2025 and reducing absolute Scope 1 and 2 emissions 44% by 2030 from a 2021 base year.
- By 2028, J&J wants 80% of suppliers by emissions in purchased goods and services and upstream transport to have science‑based climate targets.
- ESG performance helped J&J maintain an A‑ CDP score, inclusion in FTSE4Good for the 24th year, and a 2024 EcoVadis score of 74, placing it in the 95th percentile of its sector.
- J&J invested 17.2 billion dollars in R&D in 2024, and contributed 5.0 billion dollars in products and cash to social and health programs, integrating impact with its business model.
Source
https://healthforhumanityreport.jnj.com/2024/
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
https://net0tracker.com/corporates.html/Johnson%20&%20Johnson/
https://palevioletred-weasel-394267.hostingersite.com/johnson-johnson/
Net Zero and Carbon Emissions
J&J’s climate strategy centers on net zero by 2045, with operational emissions cuts and supplier engagement as the main levers. The company’s operational emissions are already on a downward trajectory, while total value‑chain emissions still dominate its footprint.
- J&J targets a 44% reduction in absolute Scope 1 and 2 GHG emissions by 2030 from a 2021 base, aligned with an interim goal of carbon neutrality in operations by 2030.
- In 2024 total operational emissions (Scopes 1 and 2) were 775,554 tCO₂e, down 1.7% from 2023, with Scope 1 at 314,690 tCO₂e.
- Scope 3 emissions were 6,597,133 tCO₂e in 2024, forming the bulk of a total footprint of 7,372,687 tCO₂e, though Scope 3 has fallen about 61% since 2019 based on Tracenable data.
- J&J reports that its Scope 1 and 2 emissions intensity fell 34% by revenue relative to 2021, reaching 5 tCO₂e per million dollars in 2024.
- Net Zero Tracker notes that J&J’s net‑zero target covers Scopes 1, 2, and 3, with a 100% reduction for Scope 1 and 2 from a 2016 base by 2030 and full value‑chain net zero by 2045.
Water Stewardship
J&J treats water as a shared resource and focuses on efficiency, reuse, and risk‑based management at sites in water‑stressed regions. Water stewardship is framed in policy documents that recognize the human right to water and commit to minimizing withdrawals and improving wastewater quality.
- Total water withdrawn fell from 11.11 million m³ in 2022 to 7.30 million m³ in 2023 and 7.43 million m³ in 2024, a reduction of roughly 33% over two years.
- J&J commits to reduce water demand, increase re‑use, and prioritize actions based on location‑specific water risks, using engineering improvements and water‑recycling projects at manufacturing sites.
- All J&J manufacturing plants have at least secondary wastewater treatment, with some using advanced technologies to remove active pharmaceutical ingredients before discharge.
- Policy statements explicitly recognize the human right to water and link water stewardship to UN Sustainable Development Goals 6 and 12.
- J&J’s environmental management system covers water, with 97% of manufacturing and R&D sites certified to ISO 14001 in 2024, up from 89% in 2023.
Regenerative Agriculture
J&J is not an agricultural company, but it touches land and ecosystems through paper, pulp, and plant‑based ingredients, and it channels part of its climate approach into nature‑based and circular material solutions. Consumer Health and MedTech operations link sustainable sourcing with packaging and device materials that reduce extraction pressure.
- J&J Consumer Health has committed 800 million dollars through 2030 to make products more sustainable, including shifts to certified and post‑consumer recycled paper and pulp packaging.
- Packaging commitments include 100% recycled plastic in bottles for major brands such as Aveeno, Johnson’s, Listerine, Neutrogena, and OGX by 2030, which reduces demand for virgin fossil‑based resin.
- Swiss MedTech recycling pilots recover materials from single‑use operating room devices in 14 countries, returning metals and plastics to material cycles and cutting hospital waste.
- J&J participates in nature‑based climate solutions to complement emission reductions, including projects that restore ecosystems and generate verified removals.
- Internal policies call for sustainable forest products and paper sourcing, which indirectly support regenerative forestry and reduced deforestation risk.
Deforestation and Biodiversity
J&J’s biodiversity approach is embedded in environmental stewardship and sourcing policies that address paper, palm‑based materials, and pharmaceutical discharges that may affect aquatic ecosystems. The company is part of sector efforts to manage deforestation risks in packaging and raw materials.
- Environmental policies commit to sustainable management of forest‑derived materials, including certified and post‑consumer recycled paper and pulp for packaging.
- Healthy Lives Mission investments of 800 million dollars through 2030 include improving sourcing of oats and flavor oils using eco‑friendly farming practices, which support soil health and biodiversity at supplier farms.
- J&J’s environmental stewardship statement highlights measures to reduce emissions and pollutants that threaten ecosystems, including controls on ozone‑depleting and high global‑warming‑potential refrigerants.
- Roche‑style benchmarks show peers already tracking phosphorus and water‑risk indicators, setting a precedent for J&J to deepen biodiversity indicators beyond current qualitative policies.
- In Europe, MedTech recycling of devices recovers up to 50 individual parts per instrument, lowering demand for new extracted metals and plastics.
Packaging and Circular Economy
Packaging is a central lever in J&J’s environmental strategy, especially in Consumer Health, where Healthy Lives Mission aims for 100% circular packaging and higher recycled content. MedTech is also piloting take‑back and recycling programs for single‑use medical devices.
- J&J Consumer Health brands aim for 100% recyclable, reusable, or compostable plastic packaging and certified / post‑consumer recycled paper and pulp packaging by 2025.
- The same initiative targets 100% recycled plastic in bottles for Aveeno, Johnson’s, Listerine, Neutrogena, and OGX by 2030, scaling demand for recycled resin and enabling bottle‑to‑bottle loops.
- Hospitals in 14 countries now participate in J&J’s recycling program for single‑use medical devices, which keeps high‑value metals and polymers in circulation.
- Waste data show that in 2023 J&J generated 121,068 tonnes of waste, of which 83.02% was recovered through recycling, reuse, or composting, while 16.98% was disposed via landfill or incineration.
- In 2024 waste diverted from disposal reached 125,070 tonnes against 17,446 tonnes directed to disposal, indicating a diversion rate of roughly 88%.
Human Rights and Responsible Sourcing
J&J aligns its Position on Human Rights with the UN Guiding Principles and runs a global human rights and anti‑modern slavery program that spans operations and supply chains. Supplier standards, audits, and training reinforce requirements on fair working conditions, child labor, and modern slavery.
- The 2024 Human Rights and Anti‑Modern Slavery Statement covers operations across 138,000 employees and a global supplier base across more than 100 countries.
- Supplier standards require conformance with Johnson & Johnson Responsibility Standards for Suppliers; non‑conforming suppliers can be disqualified or terminated.
- High‑risk suppliers receive SMETA 4‑pillar human‑rights audits by accredited third parties, covering labor, health and safety, environment, and business ethics.
- J&J engaged more than 1,000 suppliers to complete EcoVadis assessments in 2024, strengthening ESG data and performance tracking in the supply base.
- Human‑rights and responsible‑sourcing learning modules are mandatory for procurement teams, with additional anti‑modern slavery training offered to suppliers via the Onward Sustainability Training Program.
Nutrition and Health
For J&J, “nutrition and health” means access to medicines and medical technologies, patient safety, and product sustainability, rather than food nutrition. The company is consistently ranked among the top Access to Medicine performers and runs large donation programs for neglected diseases.
- J&J has remained in the top five companies in the Access to Medicine Index for more than ten years, ranking number five in the latest 2024 index.
- In 2024 J&J reached 1 million healthcare workers, bringing the cumulative total to 3.7 million supported since 2021 through training and capacity‑building.
- Cumulative doses of VERMOX (mebendazole) donated through WHO and private channels reached 2.6 billion doses by 2024, up from 2.4 billion in 2023.
- In 2024 131,634 patients received access to SIRTURO (bedaquiline) for multidrug‑resistant tuberculosis, although civil society groups argue that patent practices still limit generic access in some countries.
- The company contributed 5.0 billion dollars in products and cash globally in 2024, up from 4.3 billion dollars in 2022, to support health programs and communities.
Community and Social Impact
J&J’s community impact focuses on health worker support, crisis response, and health equity, often delivered through long‑term NGO partnerships. The company integrates product donations, grants, and impact investments across regions.
- According to J&J, support for health workers has reached 3.7 million people cumulatively since 2021, including 1 million in 2024 alone.
- VERMOX donation programs have delivered 2.6 billion doses since inception, focusing on children and women of reproductive age at risk of intestinal worms.
- J&J’s 2024 contributions in products and cash totaled 5.0 billion dollars, up from 4.3 billion dollars in 2022, funding health access and humanitarian programs.
- Access to Medicine Foundation notes that J&J supplies three key products for MDR‑TB, COVID‑19, and HIV through supranational procurement, with some access strategies extending beyond low‑income countries.
- The company reports that 94% of employees responded to the 2024 Credo survey, with 85% agreeing that J&J provides an inclusive work environment.
Governance and Transparency
J&J embeds ESG oversight at Board level, with an Enterprise Compliance & Risk Committee overseeing current and emerging risks, including ESG. The company publishes detailed ESG data and indices, with selected indicators assured by ERM CVS and PwC.
- In 2024 J&J’s total tax contribution was 15.0 billion dollars worldwide, down from 16.4 billion dollars in 2023 but up from 13.8 billion dollars in 2022.
- J&J reduced its Sustainalytics ESG risk rating from 22.1 to 20.1, and maintained an “A” MSCI rating and an A‑ CDP score.
- 97% of sales and marketing employees completed health care compliance training in 2024, maintaining a high level of training across three years.
- Regulatory quality remains strong, with 100% of regulatory inspections avoiding negative classifications in 2024.
- J&J includes both GRI and SASB indices in its ESG data workbook, and several environmental metrics, such as energy use and waste, are subject to limited assurance.
Source
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://healthforhumanityreport.jnj.com/2024/
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-performance-data-and-indices.xlsx
https://www.jnj.com/policies-reports
https://accesstomedicinefoundation.org/company/johnson-johnson
https://www.jnj.com/latest-news/how-johnson-and-johnson-is-improving-access-to-medicine-and-medical-supply
https://jnj.co.uk/latest-news/johnson-johnson-rises-to-2-in-ranking-of-companies-efforts-to-expand-access-to-medicines-worldwide
https://www.doctorswithoutborders.org/latest/johnson-johnson-deal-falls-short-people-tb
https://www.jnj.com/policies-reports/our-position-on-human-rights
https://www.jnj.com/policies-reports/2024-human-rights-and-anti-modern-slavery-statement
https://www.jnjvisionpro.com/en-gb/modern-slavery-act/
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
https://www.gcimagazine.com/brands-products/news/news/21874720/johnson-johnson-committing-800m-for-sustainability-of-brands
https://tracenable.com/company/johnson-and-johnson/waste-management
https://www.jnj.com/policies-reports/our-position-on-environmental-stewardship
http://simon-illustrations.com/pdf/our-position-on-water-and-waste-management.pdf
https://www.scienceindustries.ch/en/article/40633/johnson-johnson-together-for-a-healthy-future
https://www.jnj.com/policies-reports/our-position-on-environmental-stewardship
https://tracenable.com/company/johnson-and-johnson/ghg-emissions
https://net0tracker.com/corporates.html/Johnson%20&%20Johnson/
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
Technology and Innovation
J&J links sustainability to innovation in products, packaging, and operations, including on‑site renewables, energy efficiency, and recycling technologies for medical devices. The company has invested heavily in EHS programs and digital monitoring of ESG performance.
- J&J invested 800 million dollars between 2016 and 2023 in environment, health, and safety programs that include decarbonization and sustainable manufacturing improvements.
- More than 50 on‑site renewable energy systems operate across 20 countries, supported by at least 15 off‑site renewable electricity contracts.
- Renewable electricity deals in the United States, Canada, and Brazil will allow J&J to source the equivalent of 100% renewable electricity for operations in those countries when fully operational.
- Hospitals in 14 countries use J&J’s single‑use device recycling program, which disassembles instruments into up to 50 parts for material recovery.
- J&J uses ESG analytics platforms and supplier tools such as EcoVadis to evaluate more than 1,000 suppliers, improving data quality for Scope 3 and responsible sourcing.
Source
https://supplychaindigital.com/sustainability/johnson-johnson-tackling-supply-chain-emissions
https://procurementmag.com/sustainability/supplier-sustainability-programme
https://healthforhumanityreport.jnj.com/2024/
https://www.scienceindustries.ch/en/article/40633/johnson-johnson-together-for-a-healthy-future
Global Partnerships and Advocacy
J&J partners with Access to Medicine Foundation, WHO, Stop TB Partnership, and many NGOs and multilateral bodies to expand access and shape sector standards. At the same time, advocacy groups push J&J to go further on affordability and intellectual property practices.
- J&J has placed in the top three of the Access to Medicine Index for six consecutive editions, and in the top five for over a decade, reflecting sustained engagement in global health.
- Stop TB’s Global Drug Facility deal enables procurement of generic bedaquiline, yet Doctors Without Borders notes that patent practices still limit access in some high‑burden countries.
- Global health initiatives have supported 2.3 million health workers, according to J&J’s own Access to Medicine Index commentary in 2024.
- J&J participates in supplier climate engagement coalitions, targeting 80% of suppliers by emissions to set science‑based targets by 2028.
- Inclusion in coalitions that work on circular plastic packaging and environmental health equity connects J&J’s voice to broader regulatory and market shifts.
Source
https://jnj.co.uk/latest-news/johnson-johnson-rises-to-2-in-ranking-of-companies-efforts-to-expand-access-to-medicines-worldwide
https://accesstomedicinefoundation.org/company/johnson-johnson
https://www.doctorswithoutborders.org/latest/johnson-johnson-deal-falls-short-people-tb
https://www.jnj.com/latest-news/how-johnson-and-johnson-is-improving-access-to-medicine-and-medical-supply
https://supplychaindigital.com/sustainability/johnson-johnson-tackling-supply-chain-emissions
Progress vs. Target Tracker
- J&J’s operational decarbonization is broadly on track, with 26% absolute Scope 1 and 2 cuts since 2021 and a strong 34% intensity reduction.
- The 88% renewable electricity share plus regional 100% coverage in Europe and contracted capacity in the Americas point to early achievement of the 2025 electricity goal.
- Supplier SBT coverage at 28% in 2024 must nearly triple by 2028 to reach the 80% target, which will test procurement and supplier‑engagement capacity.
- Waste diversion has improved, but 17,446 tonnes still went to disposal in 2024, and there is no explicit zero‑waste‑to‑landfill date.
- Lack of recent quantified progress on packaging circularity means the 2025 100% goal is hard to judge, which is a transparency gap compared with some peers.
Source
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://tracenable.com/company/johnson-and-johnson/ghg-emissions
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
https://supplychaindigital.com/sustainability/johnson-johnson-tackling-supply-chain-emissions
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
Key Sustainability Innovations and Technologies
J&J’s most scalable sustainability impacts come from renewable energy, energy‑efficiency capital, packaging redesign, and MedTech recycling systems. These initiatives turn abstract net‑zero goals into concrete changes in sites, devices, and patient interfaces.
- J&J has installed more than 50 on‑site renewable energy systems in 20 countries and signed 15 off‑site renewable contracts, contributing to 88% renewable electricity globally.
- The company allocates up to 40 million dollars per year through its CO₂ Capital Relief Program to fund energy‑efficiency projects at its most energy‑intensive sites.
- Healthy Lives Mission commits 800 million dollars through 2030 to more sustainable products, including plant‑based wipes, compostable fibers, and recycled content for multiple consumer brands.
- Hospitals in 14 countries participate in a single‑use device recycling program, which recovers and processes up to 50 individual components per instrument and reduces OR waste.
- J&J leverages digital tools and EcoVadis to assess over 1,000 suppliers, using ESG analytics to prioritize action with the most carbon‑intensive partners.
Source
https://supplychaindigital.com/sustainability/johnson-johnson-tackling-supply-chain-emissions
https://procurementmag.com/sustainability/supplier-sustainability-programme
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
https://www.gcimagazine.com/brands-products/news/news/21874720/johnson-johnson-committing-800m-for-sustainability-of-brands
https://www.scienceindustries.ch/en/article/40633/johnson-johnson-together-for-a-healthy-future
Measurable Impacts
Recent ESG data show strong gains in renewables and waste diversion, moderate reductions in operational emissions, and steady progress on water, while social impact remains significant. Scope 3 has dropped sharply compared with 2019 but still dominates the footprint.
- Total Scope 1 and 2 emissions fell from 514,693 tCO₂e in 2022 to 430,926 tCO₂e in 2024, with intensity down from 6 to 5 tCO₂e per million dollars of revenue.
- In 2024 J&J’s total carbon footprint across Scopes 1, 2, and 3 was 7,372,687 tCO₂e, 2.28% lower than 2023, with Scope 3 at 6,597,133 tCO₂e, about 61% below 2019 levels.
- The share of electricity from renewables rose from 75% in 2022 to 87% in 2023 and 88% in 2024, supporting global and regional 100% goals.
- Total water withdrawn decreased from 11.11 million m³ in 2022 to 7.43 million m³ in 2024, while ISO 14001 certification coverage increased to 97% of manufacturing and R&D sites.
- Waste diverted from disposal increased from 100,510 tonnes in 2023 to 125,070 tonnes in 2024, as waste sent to disposal fell from 28,915 tonnes in 2022 to 17,446 tonnes in 2024.
Source
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://tracenable.com/company/johnson-and-johnson/ghg-emissions
https://tracenable.com/company/johnson-and-johnson/waste-management
Challenges and Areas for Improvement
Despite strong operational performance, J&J faces three main challenges: maintaining Scope 3 reductions at scale, closing gaps on packaging data and circularity, and responding to stakeholder scrutiny on access and DEI transparency.
- Scope 3 still accounts for about 90% of J&J’s total footprint, at 6.60 million tCO₂e in 2024, even after a reported 60.95% reduction since 2019.
- Supplier SBT coverage is only 28% by emissions in 2024, far from the 80% target for 2028, and value‑chain emissions plateaued between 2023 and 2024.
- J&J has a clear 2025 packaging commitment, but no recent public percentage of packaging that is already recyclable, reusable, or compostable, which limits external assessment of progress.
- Civil society organizations such as Doctors Without Borders argue that patent strategies on bedaquiline still limit access in some high‑burden TB countries, indicating a tension between innovation and equitable access.
- Reports in 2025 highlight that J&J has removed or diluted much of its public DEI information, raising questions about long‑term commitment to diversity disclosures.
Source
https://tracenable.com/company/johnson-and-johnson/ghg-emissions
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
https://www.doctorswithoutborders.org/latest/johnson-johnson-deal-falls-short-people-tb
https://www.hr-brew.com/stories/2025/05/09/exclusive-johnson-and-johnson-appears-to-scrub-most-dei-information-from-website
Future Plans and Long-Term Goals
J&J’s long‑term plan combines net zero 2045, carbon‑neutral operations by 2030, circular packaging by 2025, and expanded access to care, backed by supplier programs and capital for low‑carbon technologies.
- Climate goals include net‑zero emissions across Scopes 1, 2, and 3 by 2045, with a 44% cut in operational emissions by 2030 from a 2021 baseline and carbon‑neutral operations by 2030.
- By 2025 the company aims for 100% renewable electricity globally and 100% recyclable, reusable, or compostable plastic packaging across Consumer Health brands.
- Medium‑term plans call for 80% of suppliers by emissions to have SBT‑aligned climate targets by 2028, supported by training and tools.
- The 800 million dollar Healthy Lives Mission runs through 2030, funding sustainable packaging, ingredient transparency, and eco‑friendly sourcing for key brands.
- J&J plans to keep scaling access and health‑equity programs, building on 3.7 million health workers supported and multi‑billion‑dollar annual product and cash contributions.
Source
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
https://net0tracker.com/corporates.html/Johnson%20&%20Johnson/
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
https://healthforhumanityreport.jnj.com/2024/
Comparisons to Industry Competitors
This section compares J&J with Pfizer, GSK, and Roche, three global pharma peers with published ESG data, focusing on climate, energy, materials, and waste. J&J’s net‑zero timeline is similar to GSK and Roche, while Pfizer has a more aggressive 2040 goal.
Climate and Circularity Metrics
- Pfizer’s 2040 net‑zero goal is more aggressive than J&J’s 2045 target, and Pfizer already has 55% of manufacturing sites at zero‑landfill with landfill making up only 6% of waste.
- GSK has already achieved a 36% Scope 1 and 2 reduction since 2020 and aims for 80% reduction by 2030, while also targeting zero operational waste and 25% lower product and packaging impact.
- Roche’s net‑zero 2045 pathway (90% Scope 1–3 reduction) and 80% non‑hazardous waste recycling target by 2025 set a high bar on combined climate and waste performance.
- J&J’s 88% renewable electricity and nearly 90% waste diversion are competitive, but public transparency on packaging performance lags some peers with detailed circularity metrics.
- All four companies still face large Scope 3 footprints, yet Pfizer, GSK, and Roche have each articulated detailed supplier and product lifecycle plans that J&J will need to match in depth for value‑chain decarbonization.
Source
https://palevioletred-weasel-394267.hostingersite.com/pfizer-sustainability/
https://www.pfizer.com/about/responsibility/environmental-sustainability
https://cdn.pfizer.com/pfizercom/Pfizer_2024_Impact_Report-Performance_Data_02JUN2025.pdf
https://www.gsk.com/media/2a0pomqk/responsible-business-performance-report-2024.pdf
https://cesltd.com/gsks-environmental-sustainability-journey-a-pioneering-commitment/
https://www.roche.com/investors/reports/sustainability-targets-and-performance
https://assets.roche.com/f/176343/x/68d6d3b540/waste-management-fact-sheet.pdf
What to Watch: 12 to 18 Month Indicators
Three indicators over the next 12–18 months will show whether J&J is turning a strong operational base into full value‑chain transformation.
- Renewable electricity closure: Monitor whether J&J moves from 88% to 100% renewable electricity by 2025, completing deals and on‑site projects beyond Europe and the Americas and locking in low‑carbon power globally.
- Supplier SBT coverage ramp‑up: Track progress from 28% of suppliers by emissions with SBTs in 2024 to roughly 40–50% by 2026, which is needed to stay on track for the 80% by 2028 goal.
- Packaging and waste transparency: Look for disclosure of the percentage of packaging that is recyclable, reusable, or compostable and a clear date for zero‑waste‑to‑landfill, along with continued improvement from the current 88% waste diversion rate.
Source
https://healthforhumanityreport.jnj.com/2024/
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://www.jnj.com/our-societal-impact/global-environmental-sustainability/our-approach-to-climate-action
https://www.jnj.com/en-uk/latest-news/johnson-johnson-commits-800-million-to-making-more-sustainable-products
J&J sits in the top tier of healthcare sustainability performers on operational emissions, renewable energy, waste diversion, and access to medicines, but faces real tests on Scope 3 and packaging over the rest of this decade. For sustainability leaders benchmarking the company, three practical lessons stand out.
- Treat supplier engagement as a climate program in its own right, with targets, funding, and governance comparable to internal decarbonization, or the 80% SBT coverage goal will stay out of reach.
- Connect packaging, waste, and water into one resource‑efficiency program with transparent progress indicators and time‑bound landfill and leakage targets, rather than separate initiatives that lack unified metrics.
- Use J&J’s access and health‑equity track record as a template to embed measurable social outcomes alongside environmental goals, while engaging seriously with civil‑society critiques on pricing, patents, and DEI to maintain trust.
Source
https://healthforhumanityreport.jnj.com/2024/
https://healthforhumanityreport.jnj.com/2024/_assets/downloads/johnson-johnson-2024-esg-summary.pdf
https://accesstomedicinefoundation.org/company/johnson-johnson
https://www.doctorswithoutborders.org/latest/johnson-johnson-deal-falls-short-people-tb
https://www.hr-brew.com/stories/2025/05/09/exclusive-johnson-and-johnson-appears-to-scrub-most-dei-information-from-website
